share_log

HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target

Benzinga ·  May 10 02:55

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Verve Therapeutics (NASDAQ:VERV) with a Buy and maintains $15 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment